Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Apr 23, 2018 at 3:57 PM EDT

Why Some Investors May Still Look at Prothena, But With Very Different Views

Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful.…

Chris Lange | Apr 23, 2018 at 10:40 AM EDT

Can Akorn Win Its Fight Against Fresenius?

Fresenius said Sunday it would terminate its offer to acquire Akorn as the result of the latter's "failure to fulfill…

Chris Lange | Apr 23, 2018 at 9:40 AM EDT

Why Prothena Is Crashing

Prothena shares hit a multiyear low on Monday, one that had not been seen since 2013, on the heels of…

Chris Lange | Apr 22, 2018 at 10:15 AM EDT

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and…

Chris Lange | Apr 20, 2018 at 10:35 AM EDT

Will the FDA Shoot Down Eli Lilly and Incyte Again?

Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their…

Chris Lange | Apr 20, 2018 at 10:00 AM EDT

What to Expect From the Newest Biogen Collaboration

Ionis Pharmaceuticals shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen.

Chris Lange | Apr 19, 2018 at 12:50 PM EDT

Why GW Pharmaceuticals Isn’t Moving, Despite a Big First for the FDA

GW Pharmaceuticals won an FDA approval for its cannabis-derived drug, but shares were relatively muted on Thursday.

Chris Lange | Apr 19, 2018 at 10:20 AM EDT

Aceto Has a Heart Attack

There is a lot going on for Aceto in its latest update, and most of it is not good news.…

Chris Lange | Apr 18, 2018 at 11:10 AM EDT

The FDA Strikes Again at Calithera Biosciences

Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher.

Chris Lange | Apr 18, 2018 at 10:25 AM EDT

Is This the Turnaround Teligent Has Been Waiting For?

Teligent watched its shares make a solid gain on Wednesday after the firm announced a key approval from the FDA.

Chris Lange | Apr 18, 2018 at 10:20 AM EDT

Rigel Pharmaceuticals Gets No Boost From FDA Approval

Rigel Pharmaceuticals shares retreated early Wednesday despite an approval from the FDA for its treatment of thrombocytopenia.

Lee Jackson | Apr 18, 2018 at 8:20 AM EDT

4 Red-Hot Biotech Stocks to Buy Before Earnings

These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed…

Chris Lange | Apr 17, 2018 at 2:00 PM EDT

Why GW Pharmaceuticals Could Be an FDA First

GW Pharmaceuticals shares saw a solid gain on Tuesday after the FDA released some briefing documents pertaining to an upcoming…

Jon C. Ogg | Apr 17, 2018 at 11:35 AM EDT

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S.…

Chris Lange | Apr 17, 2018 at 10:40 AM EDT

Why Now Is the Best Time for Bellicum to Raise Cash

Bellicum Pharmaceuticals shares pulled back on Tuesday after the firm announced that it would be conducting a secondary offering to…

1 … 135 136 137 138 139 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Some Investors May Still Look at Prothena, But With Very Different Views

Can Akorn Win Its Fight Against Fresenius?

Why Prothena Is Crashing

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

Will the FDA Shoot Down Eli Lilly and Incyte Again?

What to Expect From the Newest Biogen Collaboration

Why GW Pharmaceuticals Isn’t Moving, Despite a Big First for the FDA

Aceto Has a Heart Attack

The FDA Strikes Again at Calithera Biosciences

Is This the Turnaround Teligent Has Been Waiting For?

Rigel Pharmaceuticals Gets No Boost From FDA Approval

4 Red-Hot Biotech Stocks to Buy Before Earnings

Why GW Pharmaceuticals Could Be an FDA First

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Why Now Is the Best Time for Bellicum to Raise Cash

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Why Some Investors May Still Look at Prothena, But With Very Different Views

Can Akorn Win Its Fight Against Fresenius?

Why Prothena Is Crashing

Eli Lilly, Amgen and More Big Pharma Earnings to Look For This Week

Will the FDA Shoot Down Eli Lilly and Incyte Again?

What to Expect From the Newest Biogen Collaboration

Why GW Pharmaceuticals Isn’t Moving, Despite a Big First for the FDA

Aceto Has a Heart Attack

The FDA Strikes Again at Calithera Biosciences

Is This the Turnaround Teligent Has Been Waiting For?

Rigel Pharmaceuticals Gets No Boost From FDA Approval

4 Red-Hot Biotech Stocks to Buy Before Earnings

Why GW Pharmaceuticals Could Be an FDA First

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Why Now Is the Best Time for Bellicum to Raise Cash

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how